Patent US12788771 covers the combination of fostroxacitabine bralpamide (fostrox) and lenvatinib for hepatocellular carcinoma and cancer metastases to the liver. The grant follows a Notice of Allowance announced on July 20, 2026. The USPTO also determined a Patent Term Adjustment of 1,001 days, compensating for administrative delays during examination, which moves expiry from April 2041 to January 2044. The combination is already patented in the EU, Japan, Australia, and Canada.

“The grant of the US patent for the fostrox plus lenvatinib combination is, together with the fostrox composition of matter patent, an important part of our strategy to protect clinically relevant combinations with fostrox in liver cancer,” says Jens Lindberg, CEO, Medivir. “The Patent Term Adjustment of 1,001 days, extending protection to January 2044, significantly strengthens the long-term commercial value of fostrox in the US, the world’s largest pharmaceutical market, at a time when the combination is being evaluated in the randomized Phase II study FLEX-HCC.”